Clinical trialObsActive not recruiting
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Active not recruiting
- Study type
- Observational
- Start
- 8 May 2019
- Expected end
- April 2025
- Enrollment
- 532 participants
- Sites
- 14
- Primary outcomes
- Overall Survival
- Sponsor
- Industry
- Results posted
- No
- Last update
- 12 February 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide data on consecutive patients that meet inclusion and exclusion criteria. Each patient will be followed up for the duration of the study or until death. The study will include two (2) cohorts: patients who received standard of care (SOC) and received irreversible electroporation (IRE) \[IRE cohort\], and patients who were treated with SOC and did not receive IRE \[SOC cohort\].